Deutsche Bank analyst Sidney Ho maintains Lam Research (NASDAQ:LRCX) with a Hold and lowers the price target from $480 to $400.
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors.
SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading
